Lyme Disease Diagnosis — ELISA, Western Blot, and the Controversies Around Chronic Lyme

  1. Why Lyme Diagnosis Is Complicated
  2. Clinical Diagnosis — When You Don't Need a Blood Test
  3. The Two-Tier Testing System — ELISA First
  4. Western Blot Interpretation
  5. Why Tests Miss Early Lyme Disease
  6. Seronegative Lyme — Is It Real?
  7. PCR Testing and Its Role
  8. The "Chronic Lyme" Controversy — What IDSA and ILADS Say
  9. What the Evidence Actually Shows
  10. New Testing Advances — C6 Peptide ELISA
  11. Research Papers
  12. Connections
  13. Featured Videos

Why Lyme Diagnosis Is Complicated

Lyme disease is one of the most diagnostically challenging infectious diseases in clinical practice — and one of the most contentious. Several factors converge to make diagnosis difficult: no single perfect test exists, symptoms overlap with dozens of other conditions, testing has known false-negative rates during early infection, and the cultural debate around "chronic Lyme" has layered medical controversy onto what should be a clinical question.

Conditions frequently confused with Lyme disease include fibromyalgia, multiple sclerosis, lupus, rheumatoid arthritis, viral syndromes (Epstein-Barr, cytomegalovirus), depression and anxiety disorders, chronic fatigue syndrome, and early Parkinson's disease. The cognitive and fatigue symptoms of Lyme disease, in particular, are nonspecific and easily attributed to other causes.

It is important to acknowledge upfront: many patients with persistent, debilitating symptoms have been dismissed by clinicians who did not take their complaints seriously or who over-relied on a negative blood test. That dismissal causes real harm. At the same time, the solution to that harm is not to accept every symptom as Lyme disease or to use non-validated tests that produce false positives. Good Lyme diagnosis requires integrating clinical picture, exposure history, testing context, and epidemiology — not any single element alone.

Clinical Diagnosis — When You Don't Need a Blood Test

The most important principle in Lyme diagnosis is this: the classic expanding rash — erythema migrans (EM) — in a patient with a history of outdoor activity in an endemic area is sufficient to diagnose Lyme disease and initiate treatment. Serology is not required and should not delay treatment in this scenario.

Erythema migrans meeting diagnostic criteria (diameter ≥5 cm, expanding, at the site of a recent tick bite or tick exposure) has a specificity approaching 100% for Lyme disease when seen in endemic areas. No other condition reliably produces this rash pattern. IDSA guidelines are explicit: when EM is present in the appropriate clinical context, treat without waiting for laboratory confirmation.

Why does this matter? Because serology will often be negative in the first two weeks of infection — the very time when the EM rash is present. A clinician who orders a Lyme test at the time of EM presentation and receives a negative result should not withhold treatment. The negative test in this context is expected and means nothing about the diagnosis. This is one of the most common and consequential clinical misunderstandings in Lyme disease management.

Beyond EM, clinical diagnosis becomes harder. Symptoms like fatigue, joint aches, and cognitive problems are common and nonspecific. In these cases, laboratory testing plays a central and necessary role — but must be interpreted with the full clinical picture in mind.

The Two-Tier Testing System — ELISA First

The current standard for laboratory diagnosis of Lyme disease in the United States is the two-tier testing system, established by the CDC and updated in 2019. The first tier is an ELISA (enzyme-linked immunosorbent assay) that detects IgM and IgG antibodies to B. burgdorferi proteins. Only positive or equivocal ELISA results proceed to the second tier (Western blot or modified second test).

ELISA sensitivity varies by disease stage:

False positives are a significant limitation of ELISA alone. Cross-reactive antibodies from Epstein-Barr virus (infectious mononucleosis), rheumatoid factor, syphilis, relapsing fever Borrelia, lupus, and other autoimmune conditions all produce positive ELISA results. This is why a positive ELISA alone is never diagnostic — it is a screening tool that requires confirmation.

The 2019 CDC update to two-tier testing now permits using a second-generation ELISA (particularly C6 peptide-based assays) as the confirmatory second tier instead of the traditional Western blot. Both approaches are accepted; the choice depends on laboratory capabilities.

Western Blot Interpretation

The Western blot separates B. burgdorferi proteins by molecular weight and detects antibodies to each protein (each appearing as a "band" on the blot). Different protein bands have different sensitivities and specificities, and the CDC has established criteria for how many bands must be present for a positive result.

IgM Western blot criteria (for early disease, first four weeks): 2 of 3 bands at 23 kDa (OspC), 39 kDa (BmpA), and 41 kDa (flagellin). The 41 kDa band is the most sensitive but least specific — it cross-reacts with many other flagellated bacteria. OspC (23 kDa) is highly Borrelia-specific but not present in all strains.

IgG Western blot criteria (for late disease): 5 of 10 bands at 18, 23, 28, 30, 39, 41, 45, 58, 66, and 93 kDa. The 5-of-10 threshold balances sensitivity against specificity — requiring all 10 would miss true cases; requiring only 1–2 would produce too many false positives.

Critical clinical rule: IgM positivity is only clinically meaningful in the first four weeks of symptoms. If a patient has had symptoms for more than four weeks and shows IgM positive/IgG negative on Western blot, this pattern most likely represents a false-positive IgM rather than early Lyme disease. True Lyme disease of more than four weeks' duration should have mounted an IgG response. This rule is frequently misunderstood and misapplied, leading to inappropriate Lyme diagnoses.

Why Tests Miss Early Lyme Disease

The human immune system takes two to six weeks to develop detectable antibodies after infection — a period called the seroconversion lag. During this window, even a perfect antibody test would be negative in a patient with true early Lyme disease. This is not a flaw in current testing; it is a fundamental feature of how adaptive immunity works.

Several scenarios amplify this problem:

The practical implication: a negative Lyme test in the first two to four weeks of possible exposure in a patient with compatible symptoms should not be interpreted as ruling out Lyme disease. Repeat testing two to four weeks later will often be positive if the infection is real. Treating empirically when clinical suspicion is high is often appropriate while awaiting seroconversion.

Seronegative Lyme — Is It Real?

True seronegative Lyme disease — confirmed infection in the absence of detectable antibodies by validated testing — is rare but documented. Case reports exist of culture-confirmed or PCR-confirmed Borrelia infection in patients who failed to seroconvert, primarily in severely immunocompromised individuals or those treated very early.

However, most clinical claims of "seronegative Lyme" in popular and alternative medicine contexts are something quite different. They involve patients who tested negative on standard CDC-approved two-tier testing but positive on tests from specialty laboratories (most notably IGeneX, Fry Laboratories, and similar facilities) that use non-standardized band inclusion criteria, non-FDA-cleared assays, or testing for co-infections with disputed diagnostic utility.

These alternative testing approaches have several documented problems: higher false-positive rates than validated assays, use of IgM criteria for chronic illness (where IgM positivity is a known false-positive marker), and band interpretations that differ from CDC criteria without published validation data. Independent laboratory proficiency surveys have found significant variability in results from non-standard Lyme labs.

This does not mean patients who tested positive on these assays are fabricating symptoms — their symptoms are real. But attributing those symptoms to Lyme disease based on non-validated testing, and then treating with prolonged antibiotics, is not evidence-based and carries its own risks. Many of these patients have other diagnosable conditions — autoimmune diseases, fibromyalgia, chronic fatigue syndrome, sleep disorders — that are treatable but different from Lyme disease.

PCR Testing and Its Role

PCR (polymerase chain reaction) directly detects B. burgdorferi DNA rather than antibodies against the bacteria. This approach has the theoretical advantage of proving active infection rather than inferring it from immune response. In practice, its utility is limited to specific clinical contexts.

Lyme arthritis: PCR on synovial fluid is the highest-yield application. Sensitivity ranges from 70 to 85% in confirmed active Lyme arthritis cases. A positive synovial PCR confirms Lyme arthritis definitively. This is clinically useful because joint fluid is more concentrated for bacterial DNA than blood, and because Lyme arthritis sometimes presents without a clear epidemiological history.

Blood PCR: Generally unreliable and not recommended for routine Lyme testing. B. burgdorferi spirochetemia is intermittent and at very low bacterial burden — the amount of circulating DNA is typically below reliable PCR detection thresholds. Negative blood PCR does not exclude Lyme disease, and its use as a screening tool would miss most true cases.

CSF PCR: Low sensitivity (10–30%) in Lyme neuroborreliosis, where the spirochetes are largely in the meningeal tissues rather than free in the CSF fluid. Intrathecal antibody index (comparing CSF and serum antibody levels) is a more reliable marker of CNS Lyme disease than direct PCR of spinal fluid.

Urine PCR: Marketed by some specialty labs for Lyme diagnosis, but not validated in peer-reviewed studies and not recommended by any major infectious disease society. Should not be used for clinical decision-making.

The "Chronic Lyme" Controversy — What IDSA and ILADS Say

The "chronic Lyme" debate represents one of the most polarized disputes in modern medicine, involving genuine scientific disagreement, patient advocacy, political pressure, and media amplification. Understanding both sides accurately is essential for patients trying to navigate their own care.

IDSA (Infectious Diseases Society of America) position: Does not recognize ongoing active B. burgdorferi infection as the cause of persistent symptoms after standard antibiotic treatment has been completed. Attributes persistent symptoms — which IDSA acknowledges are real and disabling — to post-infectious immune and inflammatory processes, not living spirochetes. Calls this post-treatment Lyme disease syndrome (PTLDS). Recommends symptomatic management, not extended antibiotics. Bases this on four NIH-sponsored randomized controlled trials and multiple cohort studies.

ILADS (International Lyme and Associated Diseases Society) position: Argues that persistent infection is possible in some patients, citing animal model studies (including mouse and primate models showing spirochete persistence despite antibiotic treatment) and patients' subjective experiences. Advocates for longer and more flexible antibiotic regimens. Has published alternative treatment guidelines that diverge significantly from IDSA recommendations.

In practice, some practitioners outside mainstream infectious disease go further than ILADS — diagnosing "chronic Lyme" using non-CDC-validated tests (IGeneX and others), treating patients for months or years with oral or IV antibiotics, and attributing a wide range of symptoms (including symptoms that began before possible Lyme exposure) to persistent spirochetal infection. The evidence base for this practice is not supported by peer-reviewed clinical trials.

The patient perspective deserves acknowledgment: many people with genuine, severe, and persistent symptoms after Lyme disease have been dismissed, undertreated for co-infections, or given incorrect diagnoses of psychiatric illness when the real problem was a mismanaged or delayed Lyme diagnosis. The failure of some mainstream clinicians to take these patients seriously has driven some patients toward alternative practitioners who take them more seriously but offer treatments that are not evidence-based.

What the Evidence Actually Shows

Four NIH-sponsored randomized controlled trials have examined whether extended antibiotic therapy benefits patients with persistent symptoms after standard Lyme disease treatment. The results are consistent:

The message from this body of evidence is nuanced: persistent symptoms are real and cause genuine suffering, but prolonged antibiotic treatment does not meaningfully improve those symptoms and carries non-trivial risks. The bacteria are likely cleared by standard antibiotic courses. What persists appears to be an immune-mediated process, a post-infectious syndrome, or potentially misdiagnosed comorbid conditions — none of which respond to antibiotics.

New Testing Advances — C6 Peptide ELISA

The C6 peptide ELISA represents the most significant advance in Lyme serological testing in recent years. It targets the invariant region 6 (IR6) of the VlsE lipoprotein — a highly conserved surface antigen expressed by B. burgdorferi during mammalian infection. Because VlsE is expressed during active infection (not just in culture), the C6 ELISA may more accurately reflect infection status than older assays targeting outer surface proteins that are more prominently expressed in ticks.

Key advantages:

The C6 ELISA is FDA-approved on multiple platforms (Wampole, Zeus, and others) and is increasingly available in clinical laboratories. It has not yet replaced the traditional two-tier system universally, but clinical laboratories are beginning to offer it as a standard or alternative option. Post-treatment decreases in C6 antibody levels have been investigated as a potential marker of treatment success, though results in clinical trials have been inconsistent.

Research is also advancing on other fronts: metabolomics-based signatures, machine-learning approaches to multiplex antibody profiling, and direct detection of Borrelia outer membrane vesicles in urine. None of these approaches is yet validated for routine clinical use, but they represent the direction of future diagnostics for a disease where current testing gaps remain clinically significant.

Research Papers

These peer-reviewed publications form the scientific foundation for current Lyme disease diagnostic standards and the evidence base around persistent disease:

  1. PMID: 27505918 — Lantos PM. Chronic Lyme disease: the controversies and the science. Expert Review of Anti-Infective Therapy.
  2. PMID: 29512646 — Marques AR. Lyme disease: a review. Current Allergy and Asthma Reports.
  3. PMID: 22162122 — Steere AC, Strle F, Wormser GP et al. Lyme borreliosis. Nature Reviews Disease Primers.
  4. PMID: 28978554 — Steere AC et al. Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide.
  5. PMID: 25941265 — Mead PS. Epidemiology of Lyme disease. Infectious Disease Clinics of North America.
  6. PMID: 21810255 — Bhate C, Schwartz RA. Lyme disease: Part II. Management and prevention. Journal of the American Academy of Dermatology.
  7. PMID: 30723038 — Rebman AW, Aucott JN. Post-treatment Lyme disease as a model for persistent symptoms in Lyme disease. Frontiers in Medicine.
  8. PMID: 31148544 — Fallon BA et al. A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. Neurology.
  9. PMID: 26809543 — Borchers AT et al. Lyme disease: a rigorous review of diagnostic criteria and treatment. Journal of Autoimmunity.
  10. PMID: 20032384 — Wormser GP et al. IDSA clinical practice guidelines for the assessment, treatment, and prevention of Lyme disease. Clinical Infectious Diseases.

Additional PubMed searches: Lyme ELISA Western blot diagnosis | C6 peptide ELISA Lyme | post-treatment Lyme disease syndrome | chronic Lyme randomized trials

Connections

Back to Table of Contents